4/12/2023 0 Comments Din oso 2768Immunotherapy monitoring Medicare reimbursement set at $7,489 awarded pan-cancer Signatera™ contract from the U.S.Performed 53,000 oncology tests in the third quarter of 2022, representing 153% growth compared to the third quarter of 2021, with 35 published peer-reviewed studies for Signatera™ to date.2022 revenue guidance raised to $810 million – $830 million, up $40 million vs.Processed approximately 517,500 tests in the third quarter of 2022, compared to approximately 407,300 tests in the third quarter of 2021, an increase of 27.1%.Product revenues grew 29.8% over the same period. Generated total revenues of $210.6 million in the third quarter of 2022 compared to $158.1 million in the third quarter of 2021, an increase of 33.2%. Recent Strategic and Financial Highlights (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported financial results for the third quarter ended September 30, 2022.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |